Therapeutic Potential of Spesolimab-Sbzo in the Management of Generalized Pustular Psoriasis Flares in Adults: Evidence to Date

References

• Song EJ, Liu C. Exploring the clinical assessment, guidelines, and options for the treatment of generalized pustular psoriasis [podcast]. Clin Cosmet Invest Dermatol. 2023;16:2911–2917. doi:10.2147/CCID.S442437
   PubMedGoogle Scholar
• Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907–919. doi:10.1080/1744666X.2019.1648209
   PubMed Web of Science ®Google Scholar
• Braun-Falco O, Berthold D, Ruzicka T. Klassifikation, Klinik und Therapie. Ubersicht und Erfahrungen an 18 Patienten [Psoriasis pustulosa generalisata--classification, clinical aspects and therapy. Review and experiences with 18 patients]. Hautarzt Z Dermatol Venerol Verwandte Geb. 1987;38(9):509–520. German.
   PubMedGoogle Scholar
• Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235–1270. doi:10.1111/1346-8138.14523
   PubMed Web of Science ®Google Scholar
• Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet Lond Engl. 2023. doi:10.1016/S0140-6736(23)01378-8
   Google Scholar
• Pereira TM, Vieira AP, Fernandes JC, Antunes H, Basto AS. Anti-TNF-alpha therapy in childhood pustular psoriasis. Dermatol Basel Switz. 2006;213(4):350–352. doi:10.1159/000096202
   PubMed Web of Science ®Google Scholar
• Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000;14(5):382–388. doi:10.1046/j.1468-3083.2000.00058.x
   PubMed Web of Science ®Google Scholar
• Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol. 2012;166(1):179–188. doi:10.1111/j.1365-2133.2011.10583.x
   PubMed Web of Science ®Google Scholar
• Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011–1017. doi:10.1111/1346-8138.13306
   PubMed Web of Science ®Google Scholar
• Böhner A, Roenneberg S, Eyerich K, Eberlein B, Biedermann T. Acute generalized pustular psoriasis treated with the IL-17A antibody secukinumab. JAMA Dermatol. 2016;152(4):482–484. doi:10.1001/jamadermatol.2015.4686
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, Phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355–362. doi:10.1111/1346-8138.13622
   PubMed Web of Science ®Google Scholar
• Ali F, Smith CH, Mahil SK. Spesolimab in the treatment of generalized pustular psoriasis: a critically appraised research paper. Br J Dermatol. 2023;188(3):328–329. doi:10.1093/bjd/ljac049
   PubMed Web of Science ®Google Scholar
• Blair HA. Spesolimab: first approval. Drugs. 2022;82(17):1681–1686. doi:10.1007/s40265-022-01801-4
   PubMed Web of Science ®Google Scholar
• Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676–684. doi:10.1111/ijd.12070
   PubMed Web of Science ®Google Scholar
• Burden AD, Okubo Y, Zheng M, et al. Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study. Exp Dermatol. 2023;32(8):1279–1283. doi:10.1111/exd.14824
   PubMed Web of Science ®Google Scholar
• Morita A, Choon SE, Bachelez H, et al. Design of effisayilTM 2: a Randomized, Double-Blind, Placebo-Controlled Study of spesolimab in preventing flares in patients with generalized pustular psoriasis. Dermatol Ther. 2023;13(1):347–359. doi:10.1007/s13555-022-00835-6
   Web of Science ®Google Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431–2440. doi:10.1056/NEJMoa2111563
   PubMed Web of Science ®Google Scholar
• David S, Hamilton JP. Drug-induced liver injury. US Gastroenterol Hepatol Rev. 2010;6:73–80.
   PubMedGoogle Scholar
• Rivera-Díaz R, Daudén E, Carrascosa JM, et al. Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment. Dermatol Ther. 2023;13(3):673–688. doi:10.1007/s13555-022-00881-0
   Web of Science ®Google Scholar
• Krueger J, Puig L, Thaçi D. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):51–64. doi:10.1007/s40257-021-00658-9
   PubMed Web of Science ®Google Scholar
• Chen P, Li C, Xue R, et al. Efficacy and safety of acitretin monotherapy in children with pustular psoriasis: results from 15 cases and a literature review. J Dermatol Treat. 2018;29(4):353–363. doi:10.1080/09546634.2017.1395798
   PubMed Web of Science ®Google Scholar
• Routhouska SB, Sheth PB, Korman NJ. Long-term management of generalized pustular psoriasis with infliximab: case series. J Cutan Med Surg. 2008;12(4):184–188. doi:10.2310/7750.2008.07036
   PubMed Web of Science ®Google Scholar
• Viguier M, Aubin F, Delaporte E, et al. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis. Arch Dermatol. 2012;148(12):1423–1425. doi:10.1001/2013.jamadermatol.80
   PubMedGoogle Scholar
• Morita A, Yamazaki F, Matsuyama T, et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label phase 3 study. J Dermatol. 2018;45(12):1371–1380. doi:10.1111/1346-8138.14664
   PubMed Web of Science ®Google Scholar
• Esposito M, Mazzotta A, Casciello C, Chimenti S. Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series. Dermatology. 2008;216(4):355–360. doi:10.1159/000117706
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Nakagawa H, Kubo Y, Ootaki K; the Japanese Brodalumab Study Group. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741–751. doi:10.1111/bjd.14702
   PubMed Web of Science ®Google Scholar
• Risankizumab: first global approval | drugs. Available from: https://link.springer.com/article/10.1007/s40265-019-01136-7. Accessed November 19, 2023.
   Google Scholar
• Warren R, Burden D, Choon SE, et al. Effect of Subcutaneous spesolimab on the prevention of generalized pustular psoriasis flares over 48 weeks: subgroup analyses from the effisayil 2 trial. Skin J Cutan Med. 2023;7(6):s245–s245. doi:10.25251/skin.7.supp.245
   Google Scholar
• SPEVIGO® prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf. Accessed November 19, 2023.
   Google Scholar
• Dattola A, Taliano A, Rallo A, Pellacani G, Richetta AG. Spesolimab for the treatment of generalized pustular psoriasis: real life experience. Ital J Dermatol Venereol. 2024;159(1):61–62. doi:10.23736/S2784-8671.23.07628-4
   PubMedGoogle Scholar
• Bellinato F, Gisondi P, Dattola A, et al. Spesolimab in patients with flare of generalized pustular psoriasis: a multicentre case-series. J Eur Acad Dermatol Venereol. 2023. doi:10.1111/jdv.19678
   Web of Science ®Google Scholar